BCHE and Alzheimer disease: Furthermore, melatonin hybrids were explored in preclinical models as multitarget agents combining antioxidant, cholinesterase-inhibitory, and monoamine oxidase-inhibitory effects, demonstrating promising interactions with donepezil and other agents for synergistic modulation of AD pathophysiology [166].